The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer

BACKGROUND: Ovarian cancer is initially responsive to frontline chemotherapy. Unfortunately, it often recurs and becomes resistant to available therapies and the survival rate for advanced and recurrent ovarian cancer is unacceptably low. We thus hypothesized that it would be possible to achieve mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Binder, Pratibha S., Hashim, Yassar M., Cripe, James, Buchanan, Tommy, Zamorano, Abigail, Vangveravong, Suwanna, Mutch, David G., Hawkins, William G., Powell, Matthew A., Spitzer, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918278/
https://www.ncbi.nlm.nih.gov/pubmed/35279106
http://dx.doi.org/10.1186/s12885-022-09367-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918278/
https://www.ncbi.nlm.nih.gov/pubmed/35279106
http://dx.doi.org/10.1186/s12885-022-09367-w

Ejemplares similares